



smiths
bringing technology to life

Interim Results

16.03.2016

Bringing technology
to life

www.smiths.com

This document contains certain statements that are forward-looking statements. They appear in a number of places throughout this document and include statements regarding our intentions, beliefs or current expectations and those of our officers, directors and employees concerning, amongst other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the business we operate. By their nature, these statements involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and, unless otherwise required by applicable law, the Company undertakes no obligation to update or revise these forward-looking statements. Nothing in this document should be construed as a profit forecast. The Company and its directors accept no liability to third parties in respect of this document save as would arise under English law. This presentation contains brands that are trademarks and are registered and/or otherwise protected in accordance with applicable law.

Andy Reynolds Smith

Chief Executive



Agenda

- H1 Performance review
- Andy Reynolds Smith
- H1 Financial performance
- Chris O'Shea
- Initial observations
- Andy Reynolds Smith
- Question & Answer session



H1 results overview

Revenue*

£1,372m
-3%

Headline
operating profit

£217m
-6%

- Revenue and headline operating profit in line with expectations
- John Crane impacted by challenging oil and gas markets; aftermarket revenues more resilient
- Continued growth at Smiths Medical
- Good profit growth at Smiths Detection
- Interim dividend 13.25 pence per share

John Crane
results impacted
by challenging
oil and gas end
markets.

- Revenue down 11% - first-fit sales declined 15%, more resilient aftermarket sales down 7%
- Margins driven lower by volumes and investment in strategic first fit projects to expand the installed base
- Action to position the business in current environment by addressing fixed costs

Revenue

£393m

-11%

Headline
profit

£78m

-24%

Headline
operating margin

19.9%

-330bps

58%
aftermarket

Non Energy 40%
Downstream 45%
Midstream 9%
Upstream 6%

Smiths Medical reported underlying revenue growth. Again.

- Continued growth in revenue and profitability driven by Infusion Systems and Vital Care
- R&D increased 50 bps to 5.8% of sales
- Emerging market sales increased – growth of 9% in China, 20% in India

Revenue

£411m

+1%

Headline
profit

£84m

+4%

Headline
operating margin

20.5%

+150bps

81%
aftermarket*

**Smiths
Detection**
management
actions delivered
profitable growth.

- Value engineering and programme management initiatives delivered revenue and margin benefit
- Strong performance in Ports & Borders, with progress in Military; offset by weakness in Transportation and Critical Infrastructure
- R&D at 5.1% of sales reflects disciplined approach to new product development

Revenue

£240m
+4%

Headline
profit

£30m
+38%

Headline
operating margin

12.4%
+210bps

38%
aftermarket

Smiths Interconnect performance stabilised.

- Restructuring and cost controls helped to stabilise performance
- Margin improvement also driven by Connectors and Power; more than offsetting Microwave performance
- Increased focus on commercial opportunities in Asia

Revenue

£196m

-3%

Headline
profit

£19m

-%

Headline
operating margin

9.7%

+50bps

Flex-Tek
delivered a solid
performance.

- Revenue and margin performance in line with expectations
- Growth in aerospace, U.S. housing and medical sectors; partly offset by some industrial commercial segments
- Further progress in China with double digit sales growth

Revenue

£132m

-1%

Headline
profit

£23m

-5%

Headline
operating margin

17.6%

-50bps

Chris O'Shea

Chief Financial Officer


H1 Financial performance




Resilient financial performance

(£m)	H1 2016	H1 2015	Underlying growth	Reported growth
Revenue	1,372	1,416	(3)%	(3)%
Operating profit	217	232	(6)%	(6)%
<i>Operating margin</i>	15.8%	16.4%	(60) bps	(60) bps
Headline free cashflow	174	132		32%
ROCE	15.4%	15.4%	-	-
Basic EPS	35.2p	38.5p	-	(9)%
Dividend per share	13.25p	13.0p	-	2%


Group revenue fell 3% on an underlying basis...




...whilst profitability remained resilient




Cash conversion exceeded 100%...



...resulting in an 32% improvement in headline free cashflow



Net debt higher due to final dividend and FX



The Group has a good range of debt maturities

Weighted average
debt facilities maturity


4.6 years

Weighted average
interest rate

4.03%

Credit ratings

**BBB+/Baa2
stable**



Substantial progress made on pensions

Pension funding exercise concluded

- Significantly lower deficits
- Schemes de-risked
- Enhanced free cash flow
- Certainty of funding over the next 3 years
- FY16 pension cash contributions of £124m is £27m less than previously stated

Annual cash contributions

Y/E July (£m)	2015	2016	2017	2018
SIPS	60	39	24	24
TIGPS	16	11	3	3
US	27	74	23	23
Total	103	124	50	50

A strong financial framework

Intelligent cost control

Reduce costs to invest in growth generating activities

Use assets more efficiently

Opportunity to improve utilisation

Optimal working capital investment

Reduce inventory and invest cash in growth

Relentless focus on cash generation

Cash as a key measure of underlying performance

Disciplined capital allocation

Deploy capital to maximise risk-adjusted returns

Andy Reynolds Smith


Chief Executive

Initial observations




Smiths Group today

Revenue by division



Revenue by destination



Employees worldwide

23,000

Engineers & scientists

3,000


Sites worldwide

350

How we look at excellence at Smiths

Technology

Smiths Detection, Wiesbaden



Customer

Smiths Medical, St Paul



Production

Smiths Interconnect, Shanghai



Supply Chain

Flex-Tek, Tennessee



Programme

Smiths Detection, Wiesbaden



People

John Crane, Tianjin



Customer intimacy

- Continuous drive to broaden and deepen customer intimacy across the Group
- Increase our customer offering in service element of delivery
- Relentlessly innovate to meet our customers' needs

Embedding ourselves as a **trusted partner with customers** - a key initiative to drive aftermarket sales.

Increase operational intensity

- Good but can be so much better
- Faster and more agile decision making
- Consistent execution across the portfolio is key
- More efficient, better flow in our operations
- Opportunities to streamline cost base

Considerable
scope for
**operational
improvements**
to unlock value.


Above market growth

Increasing aftermarket sales can help to smooth revenue profile and benefit margins.

- Target leadership positions in attractive markets to unlock long-term growth
- 80% of Group revenues come from 5 market sectors
- Only half of our top 28 product lines are growing
- Need to change our approach to focus on attractive markets and capabilities
- Plan to grow above the markets we serve


Assessing our market attractiveness and competitiveness

Revenue by market



Squaring the circle

Squaring the circle to optimise growth, investment and returns



Priorities

Customer intimacy

- Drive growth
- Address competitive positioning
- Establish continuous improvement culture

Operational intensity

- Extract operational efficiencies to free up cash
- Invest in long-term value creation

Above market growth

- Develop asset light and technology heavy business

Potential to unlock significant value

Group outlook

- Global energy markets to remain challenging in H2; taking action to position John Crane in an uncertain environment
- Smiths Medical to deliver a similar revenue performance in H2; some margin benefit
- Strong order book at Smiths Detection expected to drive revenue growth in H2; margins to moderate due to contract mix and investment
- Group performance slightly more weighted to H2 than usual
- Our expectations for the full year remain unchanged

Questions & Answers

16.03.2016

**Bringing technology
to life**

Appendix

Reconciliation of operating profit

	£m
Headline Operating Profit	217
<i>Restructuring programmes</i>	<i>(15)</i>
<i>Litigation provision: John Crane, Inc.</i>	<i>(2)</i>
<i>Litigation provision: Titeflex Corporation</i>	<i>7</i>
<i>Changes to post-retirement benefits</i>	<i>(10)</i>
Amortisation of acquired intangible assets	(9)
Legacy retirement benefits administration	(5)
Statutory operating profit	183

Normal full year translational foreign exchange impact

- A 10c movement in USD would have £15m effect on profit
- A 10c movement in EUR would have £5m effect on profit